160.43 USD
-2.93
1.79%
At close Jul 11, 4:00 PM EDT
After hours
160.43
+0.00
0.00%
1 day
-1.79%
5 days
0.08%
1 month
-3.80%
3 months
8.37%
6 months
-5.24%
Year to date
-0.11%
1 year
44.78%
5 years
249.60%
10 years
660.69%
 

About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Employees: 4,434

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

23% more repeat investments, than reductions

Existing positions increased: 234 | Existing positions reduced: 190

11% more first-time investments, than exits

New positions opened: 112 | Existing positions closed: 101

0.36% more ownership

Funds ownership: 94.67% [Q4 2024] → 95.04% (+0.36%) [Q1 2025]

0% less funds holding

Funds holding: 588 [Q4 2024] → 587 (-1) [Q1 2025]

8% less capital invested

Capital invested by funds: $19.8B [Q4 2024] → $18.2B (-$1.63B) [Q1 2025]

12% less call options, than puts

Call options by funds: $146M | Put options by funds: $165M

17% less funds holding in top 10

Funds holding in top 10: 29 [Q4 2024] → 24 (-5) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$190
18%
upside
Avg. target
$206
28%
upside
High target
$218
36%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
David Westenberg
31%upside
$210
Overweight
Maintained
15 May 2025
UBS
Elizabeth Garcia
36%upside
$218
Buy
Maintained
9 May 2025
Barclays
Luke Sergott
18%upside
$190
Overweight
Maintained
9 May 2025

Financial journalist opinion

Neutral
Business Wire
4 days ago
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (>1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY.
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
Neutral
Business Wire
1 week ago
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera in CRC surveillance Data on &gt.
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
Positive
24/7 Wall Street
1 month ago
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
A high-growth gem is the largest holding in Stanley Druckenmiller's firm's fund.
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
Neutral
Business Wire
1 month ago
Natera Announces Medicare Coverage for Signatera™ Genome
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring, mirroring the pre-existing coverage for Signatera. The coverage determination was supported by r.
Natera Announces Medicare Coverage for Signatera™ Genome
Neutral
Business Wire
1 month ago
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study analyzed the performance of Signatera Genome in a cohort of 392 patients (> 2,600 plasma samples) across five different tumor types (breast cancer, non-small cell lung cance.
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
Neutral
Business Wire
1 month ago
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analys.
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Positive
Seeking Alpha
1 month ago
Natera: The Clues In Q1 Earnings
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue.
Natera: The Clues In Q1 Earnings
Positive
Zacks Investment Research
2 months ago
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Neutral
Seeking Alpha
2 months ago
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Charts implemented using Lightweight Charts™